HomeCompareJWCTF vs QYLD

JWCTF vs QYLD: Dividend Comparison 2026

JWCTF yields 651.47% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JWCTF wins by $503577.88M in total portfolio value
10 years
JWCTF
JWCTF
● Live price
651.47%
Share price
$0.31
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$503577.90M
Annual income
$386,785,137,245.59
Full JWCTF calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — JWCTF vs QYLD

📍 JWCTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJWCTFQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JWCTF + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JWCTF pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JWCTF
Annual income on $10K today (after 15% tax)
$55,374.59/yr
After 10yr DRIP, annual income (after tax)
$328,767,366,658.75/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, JWCTF beats the other by $328,767,361,848.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JWCTF + QYLD for your $10,000?

JWCTF: 50%QYLD: 50%
100% QYLD50/50100% JWCTF
Portfolio after 10yr
$251788.96M
Annual income
$193,392,571,452.45/yr
Blended yield
76.81%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JWCTF buys
0
QYLD buys
0
No recent congressional trades found for JWCTF or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJWCTFQYLD
Forward yield651.47%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$503577.90M$25.4K
Annual income after 10y$386,785,137,245.59$5,659.31
Total dividends collected$493990.56M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: JWCTF vs QYLD ($10,000, DRIP)

YearJWCTF PortfolioJWCTF Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$75,847$65,146.58$10,352$1,192.36+$65.5KJWCTF
2$542,945$461,789.28$10,830$1,347.57+$532.1KJWCTF
3$3,670,393$3,089,441.65$11,460$1,539.07+$3.66MJWCTF
4$23,446,108$19,518,787.95$12,275$1,777.84+$23.43MJWCTF
5$141,614,527$116,527,191.03$13,323$2,078.95+$141.60MJWCTF
6$809,307,352$657,779,808.21$14,667$2,463.34+$809.29MJWCTF
7$4,379,155,354$3,513,196,486.95$16,396$2,960.57+$4379.14MJWCTF
8$22,451,936,399$17,766,240,170.59$18,631$3,612.97+$22451.92MJWCTF
9$109,152,115,265$85,128,543,318.27$21,548$4,482.15+$109152.09MJWCTF
10$503,577,900,579$386,785,137,245.59$25,398$5,659.31+$503577.88MJWCTF

JWCTF vs QYLD: Complete Analysis 2026

JWCTFStock

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

Full JWCTF Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this JWCTF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JWCTF vs SCHDJWCTF vs JEPIJWCTF vs OJWCTF vs KOJWCTF vs MAINJWCTF vs XYLDJWCTF vs JEPQJWCTF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.